Literature DB >> 19863848

Polymorphisms in serotonin-related genes in anorexia nervosa. The first study in Czech population and metaanalyses with previously performed studies.

D Martásková1, L Slachtová, D Kemlink, D Záhoráková, H Papezová.   

Abstract

Anorexia nervosa is a serious psychiatric disorder characterized by the inability to maintain normal body weight. The frequently studied polymorphisms in the serotonin 5-HT2A receptor gene (-1438A/G) and in serotonin transporter 5-HTT gene (LPR, VNTR) have led to controversial results in different populations. The aim of the study was to address association of the above-mentioned polymorphisms with anorexia nervosa in the Czech population. We genotyped a well-defined group of 75 patients with anorexia nervosa (average age of 25.39 years, SD 6.18; average BMI 14.65 (SD 1.38)). The control group consisted of 65 Caucasian healthy females (average age 25.76 years, SD 5.12; average BMI 20.69, SD 1.85). The 5-HT2A receptor -1438A/G polymorphism analysis showed a trend for the association with odds ratios for risk allele A being in the same direction. In combination with a previously published Polish cohort, the allelic test reached a suggestive borderline (P = 0.0362, chi2 statistics, 1 df). In meta-analysis which included all published results for allelic tests, the resulting P value was highly significant (0.0003, chi2 statistics, 1 df). Using quantitative association of 5-HTR2A polymorphism with BMI in the Czech sample, a borderline association (P = 0.055) was observed. In 5-HTT, LPR polymorphism analysis, unlike in 5-HT2A, neither allelic nor quantitative association with BMI for the bi-allelic 5-HTT marker was observed. Results of this study support previous reports of a significant role of the A allele (-1438A/G, 5-HT2A receptor) as a risk factor in anorexia nervosa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863848

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  8 in total

Review 1.  Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials.

Authors:  Timothy D Brewerton
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  Examining associations between disordered eating and serotonin transporter gene polymorphisms.

Authors:  Melissa A Munn-Chernoff; Matthew B McQueen; Gary L Stetler; Brett C Haberstick; Soo Hyun Rhee; Laura E Sobik; Robin P Corley; Andrew Smolen; John K Hewitt; Michael C Stallings
Journal:  Int J Eat Disord       Date:  2012-01-24       Impact factor: 4.861

3.  Family-based clinical associations and functional characterization of the serotonin 2A receptor gene (HTR2A) in autism spectrum disorder.

Authors:  Ryan M Smith; Wesley Banks; Emily Hansen; Wolfgang Sadee; Gail E Herman
Journal:  Autism Res       Date:  2014-04-17       Impact factor: 5.216

Review 4.  Genetics of Anorexia Nervosa.

Authors:  Jessica H Baker; Katherine Schaumberg; Melissa A Munn-Chernoff
Journal:  Curr Psychiatry Rep       Date:  2017-09-22       Impact factor: 5.285

5.  Genetics and Epigenetics of Eating Disorders.

Authors:  Zeynep Yilmaz; J Andrew Hardaway; Cynthia M Bulik
Journal:  Adv Genomics Genet       Date:  2015-03-10

6.  Preliminary evidence for the role of HTR2A variants in binge eating in young women.

Authors:  Rachel Koren; Alexis E Duncan; Melissa A Munn-Chernoff; Kathleen K Bucholz; Michael T Lynskey; Andrew C Heath; Arpana Agrawal
Journal:  Psychiatr Genet       Date:  2014-02       Impact factor: 2.458

7.  Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex.

Authors:  Ryan M Smith; Audrey C Papp; Amy Webb; Cara L Ruble; Leanne M Munsie; Laura K Nisenbaum; Joel E Kleinman; Barbara K Lipska; Wolfgang Sadee
Journal:  Biol Psychiatry       Date:  2012-11-13       Impact factor: 13.382

Review 8.  Contemporary views on the genetics of anorexia nervosa.

Authors:  Pei-an Betty Shih; D Blake Woodside
Journal:  Eur Neuropsychopharmacol       Date:  2016-02-20       Impact factor: 4.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.